Date: 2013-10-28
Type of information: Licensing agreement
Compound: Grastofil® filgrastim - biosimilar version of recombinant human granulocyte colony stimulating factor (G-CSF)
Company: Stada (Germany) Apotex (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On October 28, 2013, STADA Arzneimittel has strengthened its activities in the biosimilars area and in-licensed a filgrastim product from the Canadian pharmaceutical company Apotex. The biosimilar, marketed under the name Grastofil®, has received approval from the European Commission for the treatment of neutropenia in adults. STADA shall assume sales of the biosimilar for nearly all EU countries. Sales are planned to commence in 2014. Grastofil will be available in pre-filled syringes with two different active ingredient concentrations for intravenous or subcutaneous injection.
Financial terms:
Latest news:
